HSP90AA1 and colorectal carcinoma: Targeting Hsp90 in CRC is of particular interest due to high incidence of KRAS mutations and constitutive activation of Ras/Raf/MEK/Erk signaling, pathways susceptible to Hsp90 inhibition.